News about "Rare Pediatric Disease Designation "

Accro Bioscience's AC-101 Enters NMPA Rare Disease Development Pilot Program

Accro Bioscience's AC-101 Enters NMPA Rare Disease Development Pilot Program

Accro Bioscience’s AC-101, a novel selective RIPK2 inhibitor, enters the NMPA CDE Caring Plan-Extension pilot program for rare disease drug development.

Rare Pediatric Disease Designation | 14/09/2026 | By News Bureau |  191

Galibra Neuroscience Earns Dual FDA Designations for Gene Therapy Targeting Rare Neurological Disorder

Galibra Neuroscience Earns Dual FDA Designations for Gene Therapy Targeting Rare Neurological Disorder

Galibra Neuroscience has secured both Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. FDA for its investigational gene therapy for SSADH deficiency, strengthening regulatory support for a potential disease-modifying treatment aimed at addressing the genetic cause of the rare neurological disorder.

Rare Pediatric Disease Designation | 06/08/2026 | By News Bureau |  106

Atossa Therapeutics Receives FDA Orphan Drug Designation for Duchenne Therapy

Atossa Therapeutics Receives FDA Orphan Drug Designation for Duchenne Therapy

Atossa Therapeutics has received US Food and Drug Administration (FDA) Orphan Drug Designation (ODD) for (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy, further supporting the company’s development programme in rare paediatric neuromuscular diseases.

Rare Pediatric Disease Designation | 17/01/2026 | By News Bureau |  206


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members